<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146588</url>
  </required_header>
  <id_info>
    <org_study_id>02-036</org_study_id>
    <nct_id>NCT00146588</nct_id>
  </id_info>
  <brief_title>Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer</brief_title>
  <official_title>A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women With Stage I/II/IIIA Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig A. Bunnell, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects (good and bad) a combination of
      cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Each treatment cycle lasts 21 days and patients will participate in a least 4 cycles,
           but no more than 6 cycles of treatment.

        -  Patients will receive cytoxan (cyclophosphamide) and epirubicin intravenously on day 1
           of each treatment cycle. On days 4-17 of each cycle, patients will take capecitabine
           orally twice a day.

        -  While on the study patients will be required to complete a diary of they capecitabine
           treatment.

        -  Blood tests will be performed each week along with surveys at the beginning of the trial
           and certain follow-up visits to evaluate the patient's experience with the oral
           chemotherapy.

        -  Patients will be on the treatment for 12-18 weeks depending upon whether or not the
           disease progresses or the patient develops inacceptable side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the feasibility of administering cytoxan, epirubicin, and capecitabine to women with Stage I/II/IIIA breast cancer.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.</description>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Stage I-III breast cancer. If Stage I, should be deemed of
             sufficiently high risk of developing recurrent disease to warrant participation.

          -  18 years of age or older

          -  ANC &gt; 1,000/mm3

          -  Platelet count &gt; 100,000/mm3

          -  Hemoglobin &gt; 10

          -  Creatinine &lt; 2.0

          -  SGOT &lt; 2 x ULN

          -  Bilirubin &lt; 1.5mg/dl

          -  Able to swallow and retain oral medication

          -  LVEF greater than or equal to 50%

          -  ECOG performance status of 0 or 1

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Prior malignancy within 5 years (excluding squamous or basal cell skin cancers)

          -  Prior chemotherapy within 5 years

          -  Prior anthracycline therapy

          -  Serious comorbid physical or psychological condition
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Bunnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Craig A. Bunnell, MD, MPH</investigator_full_name>
    <investigator_title>Associate Chief Medical Officer</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>cytoxan</keyword>
  <keyword>epirubicin</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

